<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Medically refractory, symptomatic intracranial atherosclerotic disease has a poor prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Based on the results of the <z:chebi fb="8" ids="10033">Warfarin</z:chebi>-Aspirin Symptomatic Intracranial Disease study, the risk of ipsilateral <z:hpo ids='HP_0001297'>stroke</z:hpo> at 1.8 years is between 13 and 14% in patients with symptomatic intracranial <z:hpo ids='HP_0002621'>atherosclerosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Synergistic advances in intracranial angioplasty and stenting, modern neuroimaging techniques, and periprocedural and postprocedural antithrombotic regimens are creating new models for the diagnosis and successful endovascular treatment of intracranial stenosis </plain></SENT>
<SENT sid="3" pm="."><plain>In this article, the most recent clinical developments and concepts for the diagnosis and endovascular treatment of intracranial atherosclerotic disease are discussed </plain></SENT>
</text></document>